OsteoGeneX, a Kansas City, Kansas-based pharmaceutical company, is focused on commercializing orally administered bone building therapies directed against the target Sclerostin for chronic and acute bone disorders.
OsteoGeneX announced today that the U.S. Patent and Trademark Office has issued its patent number 8,178,099 titled “Methods of Altering Bone Growth by Administration of Sost or Wise Antagonist or Agonist” with claims covering the use of anti-sclerostin antibodies in combination with bisphosphonates to treat systemic bone density loss, i.e. osteoporosis.
This patent raises OsteoGeneX’s patent portfolio to three issued patents. The current portfolio contains 16 filed U.S. patent applications and 15 PCT patent applications. OsteoGeneX is currently inviting interested licensees to view its patent portfolio.
“This patent issuance for OGX is another important milestone as we continue to build and solidify intellectual property protection for our entire product portfolio” said Dr. Debra Ellies, CEO and President of OsteoGeneX.